WAVE Life Sciences Ltd.
WVE
$6.79
-$0.28-3.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 121.78% | 126.67% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 121.78% | 126.67% | |||
| Cost of Revenue | -10.18% | 15.13% | |||
| Gross Profit | 74.15% | 7.05% | |||
| SG&A Expenses | 5.77% | 15.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.65% | 15.25% | |||
| Operating Income | 44.57% | -0.20% | |||
| Income Before Tax | 50.94% | 1.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 50.94% | 1.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 50.94% | 1.25% | |||
| EBIT | 44.57% | -0.20% | |||
| EBITDA | 45.24% | -0.23% | |||
| EPS Basic | 55.86% | 8.04% | |||
| Normalized Basic EPS | 55.83% | 8.07% | |||
| EPS Diluted | 55.86% | 8.04% | |||
| Normalized Diluted EPS | 55.83% | 8.07% | |||
| Average Basic Shares Outstanding | 11.11% | 7.40% | |||
| Average Diluted Shares Outstanding | 11.11% | 7.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||